Ask The Expert – Learn More About the Antiepileptic Pacific Drug Trial

Does your child or adult (age 12-65) with Dup15q currently take 1-4 antiepileptic drugs at stable doses and have more than 4 seizures in a 4-week period?

Join us for an Ask The Expert with Longboard Pharmaceuticals to discuss the Pacific Study to test the safety and efficacy of LP352 in adults with Developmental and Epileptic Encephalopathy, which includes Dup15q.

Some individuals with dup15q syndrome may also be considered to have a Developmental Epileptic Encephalopathy.

Developmental and Epileptic Encephalopathy (DEE) refers to a group of severe epilepsies that are characterized both by seizures, which are often drug-resistant, as well as encephalopathy, which is a term used to describe significant developmental delay or even loss of developmental skills.

Guest Speakers: Longboard Pharma representatives, Dewey McLin III, PhD, Vice President of Medical Affairs and Chad Orevillo, Vice President, Head of Operations will share details about the study and answer questions from the parents and caregivers.